How To Stop The Rebound With Ozempic & Mounjaro

The Rebound Problem Nobody Wants to Talk About

Dr. Amin Hedayat opens this video with a stat that gets your attention: the majority of people who stop taking GLP-1 medications like Ozempic or Mounjaro regain a significant portion of the weight they lost, often within 12 months of discontinuation. This is not a secret in the medical community, but it is something that gets downplayed in the excitement around these drugs. Dr. Hedayat's video focuses on what you can actually do about it, offering a structured approach to either tapering off GLP-1s successfully or preparing for the metabolic reality of discontinuation.

The biology behind the rebound is straightforward once you understand it. GLP-1 medications work partly by reducing appetite and slowing gastric emptying. When you stop the medication, those effects go away. Your appetite returns, often with a vengeance, because your body has been in a state of reduced caloric intake and responds by upregulating hunger signals. At the same time, your metabolic rate has likely decreased as a result of weight loss (this happens with any weight-loss method, more than GLP-1s). So you have more hunger and a slower metabolism at the exact same time. That combination makes weight regain almost inevitable unless you have a specific plan to counteract it.

Dr. Hedayat is honest about the difficulty of this situation. He does not sugarcoat it by saying "just eat well and exercise." He acknowledges that the biological forces pushing you toward regain are powerful and that willpower alone is usually not enough to overcome them. This honesty is refreshing because it sets realistic expectations and motivates a more strategic approach.

The Taper Protocol: Slow and Steady

The first major recommendation is to never stop GLP-1 medications abruptly. Dr. Hedayat advocates for a gradual taper, reducing the dose over weeks or months rather than going from a therapeutic dose to zero overnight. The logic is similar to tapering off other medications that your body has adapted to. A sudden stop creates a sudden gap between what your body expects and what it gets, which triggers a stronger compensatory response.

He suggests working with your prescribing physician to create a taper schedule that reduces the dose by small increments, monitoring your weight and appetite at each step. If you see significant appetite increases or weight gain at a particular dose reduction, you can pause at that level for longer before reducing further. The goal is to find the lowest dose that maintains your progress while gradually allowing your body to readjust to operating without the medication.

This approach is not guaranteed to prevent all regain, but it gives your body more time to adapt and gives you more opportunity to build the habits that will need to carry the load once the medication is fully discontinued. Dr. Hedayat frames the taper period as a training ground for the post-medication phase.

Building the Infrastructure Before You Stop

The second major focus of the video is on building what Dr. Hedayat calls "metabolic infrastructure" before discontinuation. This means establishing the diet, exercise, sleep, and stress management habits that will maintain your weight loss when the pharmacological support is gone. The key insight here is that these habits need to be in place and well-established while you are still on the medication, not something you scramble to develop after you stop.

Specifically, he recommends a resistance training program that builds or maintains lean muscle mass. Muscle is metabolically active tissue that increases your resting metabolic rate, which partially counteracts the metabolic slowdown that comes with weight loss. He recommends starting strength training well before you plan to discontinue the GLP-1, giving yourself several months to build meaningful muscle and establish the exercise habit.

On the diet side, he advocates for a protein-forward eating pattern that emphasizes satiety. High protein intake (he suggests 0.7-1.0 grams per pound of body weight) helps manage appetite naturally, preserves muscle mass during any residual weight loss, and has a higher thermic effect than carbohydrates or fat, meaning your body burns more calories digesting protein. Building this eating pattern while you are on the medication and your appetite is still suppressed makes it easier than trying to adopt it after discontinuation when hunger is driving you toward calorie-dense convenience foods.

What the Video Gets Right and What It Could Add

Dr. Hedayat's approach is more practical and more honest than most content about stopping GLP-1s. He does not pretend that stopping is easy, he does not suggest that everyone should stop, and he does not shame people who choose to stay on medication long-term. His taper protocol is sensible, and his emphasis on building habits before discontinuation is excellent advice that applies to any medication-assisted weight-loss approach.

What the video could add is more discussion about when it is perfectly reasonable to stay on GLP-1 medication indefinitely. Obesity is a chronic condition, and there is growing consensus in the medical community that long-term or lifelong medication use may be appropriate for many patients, just as we treat hypertension or diabetes with ongoing medication. The framing of the video implicitly assumes that stopping is the goal, which may not be the right frame for everyone. Some people would benefit from hearing that staying on a maintenance dose is a legitimate, medically supported choice.

The psychological component of GLP-1 discontinuation deserves more attention than most medical discussions give it. Dr. Hedayat acknowledges that many patients develop an emotional relationship with the medication that goes beyond its pharmacological effects. After months or years of feeling in control of their appetite and seeing the scale move in the right direction, the prospect of losing that support can trigger real anxiety. This anxiety is not irrational. It is based on the very real statistical likelihood of regain. But it can be managed through a combination of realistic expectation-setting, gradual transitions, and psychological support from a therapist familiar with weight management issues. Treating the emotional dimension of discontinuation as seriously as the metabolic dimension leads to better outcomes and a healthier relationship with food and body image regardless of what the scale says.

Dr. Hedayat also discusses the role of metabolic testing during the taper period. Rather than just monitoring weight, he suggests tracking objective metabolic markers like fasting insulin, HOMA-IR, lipid panels, and inflammatory markers at regular intervals during dose reduction. These markers can provide early warning if your metabolic health is deteriorating even before significant weight regain shows up on the scale. If your markers start moving in the wrong direction at a particular dose reduction step, that is a signal to pause the taper and potentially increase lifestyle interventions before reducing the dose further. This data-driven approach to tapering is more precise than simply reducing the dose on a fixed schedule and hoping for the best.

Sleep deserves special emphasis during the discontinuation process. Research has consistently shown that poor sleep quality and insufficient sleep duration impair insulin sensitivity, increase appetite-stimulating hormones, reduce willpower and decision-making capacity, and promote fat storage. All of these effects directly counteract your weight-maintenance efforts. Dr. Hedayat suggests that optimizing sleep should be a priority before and during any GLP-1 taper, and that unresolved sleep issues like obstructive sleep apnea should be treated aggressively. If your GLP-1 therapy helped resolve or improve sleep apnea, and that condition returns when you reduce the dose, the downstream metabolic effects can create a vicious cycle that accelerates weight regain.

The video could benefit from discussing the role of accountability structures in maintaining weight loss after stopping GLP-1 therapy. Regular check-ins with a provider, ongoing food logging even if temporary, a consistent weigh-in schedule, and a community of people going through similar transitions all provide external accountability that can partially substitute for the internal appetite regulation that the medication was providing. These structures work best when they are established before discontinuation, so that the habits and support systems are already in place when the pharmacological support is removed. Waiting until you are already regaining weight to seek out accountability is possible but significantly harder.

Questions to Ask Your Doctor About Discontinuation

If you are thinking about coming off your GLP-1, bring these questions to your provider. Is now the right time to attempt discontinuation, or should I wait until I have established stronger lifestyle habits? Can we create a specific taper schedule rather than stopping abruptly? What is your threshold for restarting the medication if I experience significant regain? Should I increase my monitoring frequency during and after the taper? Are there other medications that might help bridge the gap during discontinuation? And honestly, is long-term maintenance on a lower dose a better option for my specific situation?

Who Should Watch This

This video is most relevant if you are currently on an Ozempic, Wegovy, or Mounjaro and are thinking about stopping, whether by choice, due to cost, or because of side effects. It is also valuable viewing if you are just starting a GLP-1 and want to plan ahead for eventual discontinuation from day one. The advice about building metabolic infrastructure early applies to everyone on these medications. If you are a prescriber who works with GLP-1 patients, the taper framework provides a useful conversation starter for patients who bring up discontinuation.